Yang Chi-Chun, Tsai Chieh-Chih
Department of Ophthalmology, Taipei Veterans General Hospital, Taipei 112, Taiwan.
School of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.
J Pers Med. 2024 Aug 31;14(9):927. doi: 10.3390/jpm14090927.
Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALToma) is typically treated with radiotherapy. Some studies suggested a "wait and watch" approach due to the adverse effects of radiotherapy. However, the benefits of observation for localized conjunctival MALToma remain unclear. Therefore, we aimed to explore the clinical course of early-stage conjunctival MALToma, distinguish heterogeneity between T1 and T2 patients, and identify prognostic factors.
This retrospective study involved patients with stage T1-T2 conjunctival MALToma and lasted >6 months. Clinical characteristics were compared between T1 and T2 subjects. Prognostic factors were examined with Cox regression.
The research comprised 32 subjects with early-stage conjunctival MALToma, of whom 25% underwent observation. No individuals expired regardless of choosing observation or radiotherapy. The T1 patients were younger ( = 0.002) and more inclined towards observation only ( = 0.035) than the T2 subjects. Despite more of the T1 patients undergoing watchful waiting than the T2 subjects, the T1 patients seemed to have longer systemic relapse-free survival than the T2 subjects (17 vs. 13 years, = 0.343). CD43 may imply poor prognosis ( = 0.049).
Careful observation may be suggested for early-stage conjunctival MALToma. While more of the T1 individuals were younger and chose observation than the T2 patients, survival seemed longer in the T1 subjects without significance. CD43 may indicate shorter survival in early-stage cases.
原发性眼附属器黏膜相关淋巴组织淋巴瘤（MALToma）通常采用放射治疗。一些研究由于放射治疗的不良反应而建议采用“观察等待”方法。然而，对于局限性结膜MALToma进行观察的益处仍不明确。因此，我们旨在探讨早期结膜MALToma的临床病程，区分T1和T2患者之间的异质性，并确定预后因素。
这项回顾性研究纳入了T1 - T2期结膜MALToma患者，病程超过6个月。比较了T1和T2受试者的临床特征。采用Cox回归分析预后因素。
该研究包括32例早期结膜MALToma患者，其中25%接受了观察。无论选择观察还是放疗，均无患者死亡。T1患者比T2受试者更年轻（P = 0.002），且更倾向于仅接受观察（P = 0.035）。尽管T1患者接受观察等待的比例高于T2受试者，但T1患者的无全身复发生存期似乎比T2受试者更长（17年对13年，P = 0.343）。CD43可能提示预后不良（P = 0.049）。
对于早期结膜MALToma，可能建议进行仔细观察。虽然T1患者比T2患者更年轻且选择观察的比例更高，但T1受试者的生存期似乎更长，但无统计学意义。CD43可能提示早期病例生存期较短。
